Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2012 Jan;10(1):85-93. doi: 10.1586/eri.11.152.

Candida albicans dimorphism as a therapeutic target.

Author information

1
Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knoell Institute Jena, Beutenbergstra├če 11a, D-07745, Jena, Germany.

Abstract

The ability to switch between yeast and hyphal growth forms (dimorphism) is one of the most discussed and best investigated virulence attributes of the human pathogenic fungus Candida albicans. Both morphological forms seem to be important for virulence and have distinct functions during the different stages of disease development, including adhesion, invasion, damage, dissemination, immune evasion and host response. In this review, we will provide an overview of the known and potential roles of C. albicans dimorphism and will discuss the potential benefit of drugs that can inhibit the morphological transition.

PMID:
22149617
DOI:
10.1586/eri.11.152
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center